Boswellia Serrata
Indian Frankincense · Boswellic Acids · AKBA · 5-Loxin · Salai Guggul · Shallaki
Indian frankincense — a 5-LOX inhibitor that cuts joint pain through a pathway NSAIDs don't touch.
Boswellia serrata is a resin extract whose boswellic acids inhibit 5-lipoxygenase (5-LOX), reducing osteoarthritis pain and stiffness in RCTs — a mechanism distinct from NSAIDs and curcumin, which is why it stacks rather than overlaps.
The Boswellia Serrata market in numbers
Our independent analysis of 10 boswellia serrata products, scored on three proprietary indices — the SAC Product Score™, Transparency Index™, and real Cost-Per-Effective-Dose™. Updated June 2026.
| # | Product | SAC Product Score™ | TXI™ | CPED™ | |
|---|---|---|---|---|---|
| 1 | NOW Boswellia Extract 500 mgCapsule | 9.1 | 20 | $0.18 | Under-dosed |
| 2 | Life Extension 5-LOXIN BoswelliaCapsule | 9.0 | 40 | $0.50 | Most transparent |
| 3 | Terry Naturally CuraminTablet | 8.8 | 40 | $1.33 | |
| 4 | Pure Encapsulations BoswelliaCapsule | 8.6 | 20 | $0.40 | Under-dosed |
| 5 | Swanson BoswelliaCapsule | 8.2 | 20 | $0.24 | Under-dosed |
| 6 | Nutricost Boswellia ExtractCapsule | 8.0 | 0 | $0.17 | Under-dosed |
| 7 | Solgar Full Spectrum BoswelliaCapsule | 7.9 | 20 | $0.60 | Under-dosed |
| 8 | Himalaya Boswellia (Shallaki)Caplet | 7.6 | 20 | $0.40 | Under-dosed |
| 9 | Nature's Way BoswelliaTablet | 7.5 | 20 | $0.60 | Under-dosed |
| 10 | Double Wood BoswelliaCapsule | 7.3 | 30 | $0.08 | Under-dosed |
Methodology. SAC Product Score™ blends our editorial rating (RCT quality, dose, safety, value) 50/50 with community ratings. Transparency Index™ (0-100) = third-party certification (0-50) + public batch COA (0-30) + dose honesty (0-20). Cost-Per-Effective-Dose™ is the real price of one clinical dose, not one marketed "serving". Free to cite with attribution to Super Achiever.
NOW Boswellia Extract 500 mg
What is Boswellia Serrata?
Boswellia serrata is the gum resin of a tree native to India — the source of Indian frankincense, used in Ayurvedic medicine for inflammatory conditions for centuries. The active compounds are the boswellic acids, a family of pentacyclic triterpenes, of which AKBA (acetyl-11-keto-β-boswellic acid) is the most potent and the one modern standardised extracts are built around.
The practical buyer story is standardisation. Raw 'boswellia' powder, or an extract that only lists total boswellic acids, is not the same as an extract standardised to a defined AKBA percentage. The clinical trials used specific standardised preparations — for example 5-Loxin, an extract enriched to 30% AKBA — at defined doses. So a useful boswellia supplement states either an AKBA percentage or a named standardised extract, not just 'boswellia 500 mg'. This is the same form-over-milligrams lesson that applies to curcumin.
Boswellia is also one of the few joint supplements with a credible second use: inflammatory bowel conditions. The same 5-LOX inhibition that calms joints has been studied in ulcerative colitis and Crohn's, which is why it appears in both the joint-health and the inflammation goal — it's a genuinely systemic anti-inflammatory, not a joints-only product.
How it works
Boswellia's defining mechanism is inhibition of 5-lipoxygenase (5-LOX), the enzyme that converts arachidonic acid into leukotrienes — a class of potent inflammatory mediators distinct from the prostaglandins that NSAIDs target via COX. This matters practically: because boswellia works on a DIFFERENT inflammatory pathway than NSAIDs (COX) and a different one than curcumin (which acts mainly through NF-κB), it complements rather than duplicates them. Stacking boswellia with curcumin and omega-3 hits three separate arms of the inflammatory cascade.
The osteoarthritis evidence is solid for a botanical. Kimmatkar 2003 (PMID 12622457) ran a randomised, double-blind, placebo-controlled crossover trial of a standardised Boswellia serrata extract in knee-OA patients and found significant reductions in pain and improvements in function versus placebo within eight weeks. Sengupta 2008 (PMID 18667054) tested 5-Loxin (an AKBA-enriched extract) at 100 and 250 mg/day in a larger placebo-controlled trial and found significant, dose-related improvements in pain and physical function — with benefits appearing within as little as a week at the higher dose, faster than most joint supplements.
The speed is part of boswellia's appeal: where collagen and glucosamine act over months, boswellia's anti-inflammatory action shows up in weeks, sometimes days. The trade-off is that it's an anti-inflammatory, not a cartilage-rebuilder — it manages symptoms by damping inflammation rather than altering the structural course of the disease.
At-a-glance facts
- Active compounds
- Boswellic acids, especially AKBA — look for AKBA % standardisation (e.g. 5-Loxin = 30% AKBA)
- Trial dose
- 100-250 mg/day of AKBA-enriched extract (Sengupta 2008), or ~333 mg standardised extract 3x/day (Kimmatkar 2003)
- Mechanism
- 5-LOX inhibitor → blocks leukotrienes (a pathway NSAIDs + curcumin don't target)
- Time to felt effect
- Fast for a joint supplement — 1-4 weeks, sometimes days at higher AKBA doses
- Second use
- Studied for inflammatory bowel conditions (ulcerative colitis, Crohn's) — same 5-LOX mechanism
- Timing
- With food; split doses for steadier levels
- Cost range (US)
- $12-30 / month for a properly standardised extract
- Stack synergy
- Curcumin (NF-κB) + Omega-3 (resolution) + Boswellia (5-LOX) = three-pathway anti-inflammatory base
Evidence: Good RCT support for osteoarthritis. Kimmatkar 2003 (PMID 12622457) found a standardised Boswellia serrata extract significantly reduced knee-OA pain + improved function versus placebo within 8 weeks; Sengupta 2008 (PMID 18667054) showed AKBA-enriched 5-Loxin produced dose-related pain/function improvements, with effects emerging within a week at 250 mg/day. The 5-LOX mechanism is well-characterised and distinct from NSAIDs and curcumin.
Who it's for — and who it isn't
- People with knee or general osteoarthritis who want faster relief — boswellia's anti-inflammatory effect shows in weeks, sometimes days (Sengupta 2008)
- Anyone already taking curcumin or omega-3 who wants to stack — boswellia hits 5-LOX, a separate pathway, so it adds rather than overlaps
- People who don't tolerate NSAIDs well — boswellia delivers anti-inflammatory pain relief through a non-COX mechanism
- Those with inflammatory bowel conditions exploring adjuncts — the same 5-LOX inhibition has been studied in ulcerative colitis and Crohn's (discuss with your doctor)
- Buyers willing to read the label for an AKBA percentage or a named standardised extract — that's the form the trials used
- Anyone expecting cartilage repair — boswellia manages inflammation/symptoms; it doesn't rebuild joint structure
- People who buy unstandardised 'boswellia 500 mg' with no AKBA % — that's not the form the evidence tested
- Pregnant or breastfeeding women — traditionally avoided; safety data are insufficient
- Anyone on immunosuppressants or with autoimmune disease — its immune-modulating activity warrants a doctor's input first
Week-by-week, what happens
- Days 5-7At the higher AKBA dose (250 mg/day), early pain relief can appear this fast (Sengupta 2008) — unusually quick for a joint supplement.
- Week 2-4Pain and stiffness reductions consolidate; physical-function scores improve. Most users have a clear read on whether it's working by now.
- Week 4-8Full benefit window (Kimmatkar 2003 timeline). Pair with curcumin/omega-3 for a multi-pathway effect on stubborn joints.
- OngoingMaintenance. Benefits persist with continued use; boswellia manages inflammation rather than curing the underlying joint changes, so effects fade if stopped.
Safety & contraindications
- Generally well tolerated; the most common complaints are mild GI symptoms (nausea, acid reflux, loose stools), usually dose-related and reduced by taking it with food.
- Avoid in pregnancy and breastfeeding — traditional sources caution against it and modern safety data are insufficient.
- Immune-modulating activity: if you have an autoimmune condition or take immunosuppressants, get a doctor's input before starting.
- Possible interactions with drugs metabolised by the liver's CYP enzymes — if you take prescription medication, check with a pharmacist.
- Buy an extract standardised to a stated AKBA percentage (or a named clinical extract like 5-Loxin) from a brand that publishes third-party testing — unstandardised boswellia is the form that under-delivers.
All articles on Boswellia Serrata
Best Boswellia Supplements
Boswellia serrata ranked by AKBA standardisation first (the enriched extracts the trials used beat raw 'boswellia 500 mg'), then dose, testing, and value.
Read →Double Wood Boswellia Review
The sensible bulk refill once you know boswellia works for you.
Read →Himalaya Boswellia Shallaki Review
The Ayurvedic-heritage boswellia, with genuine provenance.
Read →Life Extension 5-LOXIN Boswellia Review
The AKBA-enriched extract that matches the evidence exactly.
Read →Nature's Way Boswellia Review
Standardized, TRU-ID DNA-verified boswellia from an established brand.
Read →NOW Boswellia Extract 500 mg Review
The safe default first boswellia bottle.
Read →Nutricost Boswellia Extract Review
High-strength 65% boswellic acid extract at a true budget price.
Read →Pure Encapsulations Boswellia Review
The cleanest boswellia label, for sensitive and transparency-first buyers.
Read →Solgar Full Spectrum Boswellia Review
A full-spectrum extract from a trusted legacy brand.
Read →Swanson Boswellia Review
The cheapest boswellia that's still genuinely standardised.
Read →Terry Naturally Curamin Review
Two anti-inflammatory pathways, one bottle, branded actives.
Read →FAQ
How is boswellia different from curcumin for joints?
They work on different inflammatory pathways, which is exactly why they stack so well. Curcumin acts mainly upstream through NF-κB (lowering many cytokines and COX-2); boswellia is a 5-LOX inhibitor, blocking the leukotriene branch of inflammation that neither NSAIDs nor curcumin touch directly. So combining them — ideally with omega-3, which fuels the body's inflammation-resolution pathways — hits three separate arms of the cascade. Boswellia also tends to act faster (sometimes within a week), where curcumin's joint benefit builds over several weeks.
What does 'AKBA' mean and why does it matter?
AKBA (acetyl-11-keto-β-boswellic acid) is the most potent of boswellia's active boswellic acids, and it's what the clinical trials standardised around. A raw 'boswellia 500 mg' capsule with no AKBA percentage isn't necessarily the form the evidence tested. Look for an extract standardised to a stated AKBA % (5-Loxin, for example, is enriched to ~30% AKBA) or a named clinical extract — that's how you buy the version the trials actually used.
How fast does boswellia work?
Fast, for a joint supplement. In Sengupta 2008 (PMID 18667054), the AKBA-enriched extract at 250 mg/day produced significant pain relief within as little as a week — much quicker than collagen or glucosamine, which take months. That speed comes from its mechanism: it's an active anti-inflammatory, so it damps the inflammatory drivers of pain quickly rather than slowly rebuilding tissue. Give it 1-4 weeks to judge.
Can boswellia help with gut inflammation too?
There's a credible, though smaller, evidence base for it. The same 5-LOX inhibition that calms joints has been studied in inflammatory bowel conditions like ulcerative colitis and Crohn's, with some encouraging results. This is why boswellia sits in both our joint-health and inflammation hubs — it's a genuinely systemic anti-inflammatory. If you're considering it for a diagnosed GI condition, do it with your gastroenterologist rather than as self-treatment.
Sources & further reading
- Kimmatkar 2003 (knee OA RCT)Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee — a randomized double blind placebo controlled trial
Randomised, double-blind, placebo-controlled crossover trial in knee-OA patients: a standardised Boswellia serrata extract significantly reduced knee pain, improved function, and increased walking ability versus placebo over 8 weeks, with good tolerability.
- Sengupta 2008 (5-Loxin, dose-response)A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee
Placebo-controlled trial of AKBA-enriched Boswellia extract (5-Loxin) at 100 and 250 mg/day in knee OA: significant, dose-related reductions in pain and improvements in physical function, with benefits appearing within ~7 days at the 250 mg dose.